Lassa fever—the road ahead
RF Garry - Nature Reviews Microbiology, 2023 - nature.com
Lassa virus (LASV) is endemic in the rodent populations of Sierra Leone, Nigeria and other
countries in West Africa. Spillover to humans occurs frequently and results in Lassa fever, a …
countries in West Africa. Spillover to humans occurs frequently and results in Lassa fever, a …
Single-dose mucosal replicon-particle vaccine protects against lethal Nipah virus infection up to 3 days after vaccination
SR Welch, JR Spengler, SC Genzer… - Science …, 2023 - science.org
Nipah virus (NiV) causes a highly lethal disease in humans who present with acute
respiratory or neurological signs. No vaccines against NiV have been approved to date …
respiratory or neurological signs. No vaccines against NiV have been approved to date …
Third international conference on Crimean-Congo hemorrhagic fever in Thessaloniki, Greece, September 19–21, 2023
Abstract The Third International Conference on Crimean-Congo Hemorrhagic Fever (CCHF)
was held in Thessaloniki, Greece, September 19–21, 2023, bringing together a diverse …
was held in Thessaloniki, Greece, September 19–21, 2023, bringing together a diverse …
Delayed low-dose oral administration of 4′-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease
SR Welch, JR Spengler, JB Westover… - Science Translational …, 2024 - science.org
Development of broad-spectrum antiviral therapies is critical for outbreak and pandemic
preparedness against emerging and reemerging viruses. Viruses inducing hemorrhagic …
preparedness against emerging and reemerging viruses. Viruses inducing hemorrhagic …
Understanding immune responses to Lassa virus infection and to its candidate vaccines
H Murphy, H Ly - Vaccines, 2022 - mdpi.com
Lassa fever (LF) is a deadly viral hemorrhagic fever disease that is endemic in several
countries in West Africa. It is caused by Lassa virus (LASV), which has been estimated to be …
countries in West Africa. It is caused by Lassa virus (LASV), which has been estimated to be …
Replicon particle vaccination induces non-neutralizing anti-nucleoprotein antibody-mediated control of Crimean-Congo hemorrhagic fever virus
TE Sorvillo, E Karaaslan, FEM Scholte, SR Welch… - npj Vaccines, 2024 - nature.com
Crimean-Congo hemorrhagic fever virus (CCHFV) can cause severe human disease and is
considered a WHO priority pathogen due to the lack of efficacious vaccines and antivirals. A …
considered a WHO priority pathogen due to the lack of efficacious vaccines and antivirals. A …
Lassa virus replicon particle vaccine protects strain 13/N guinea pigs against challenge with geographically and genetically diverse viral strains
Lassa virus (LASV) causes mild to severe hemorrhagic fever disease in humans. Strain 13/N
guinea pigs are highly susceptible to infection with LASV strain Josiah (clade IV), providing …
guinea pigs are highly susceptible to infection with LASV strain Josiah (clade IV), providing …
Activation of protein kinase receptor (PKR) plays a pro-viral role in mammarenavirus-infected cells
H Witwit, R Khafaji, A Salaniwal, AS Kim… - Journal of …, 2024 - Am Soc Microbiol
Many viruses, including mammarenaviruses, have evolved mechanisms to counteract
different components of the host cell innate immunity, which is required to facilitate robust …
different components of the host cell innate immunity, which is required to facilitate robust …
Prothrombin Time, Activated Partial Thromboplastin Time, and Fibrinogen Reference Intervals for Inbred Strain 13/N Guinea Pigs (Cavia porcellus) and Validation of …
JA Condrey, T Flietstra, KM Nestor, EL Schlosser… - Microorganisms, 2020 - mdpi.com
Inbred strain 13/N guinea pigs are used as small animal models for the study of hemorrhagic
fever viruses. Coagulation abnormalities, including prolonged clotting times and bleeding …
fever viruses. Coagulation abnormalities, including prolonged clotting times and bleeding …
Crimean-Congo hemorrhagic fever virus replicon particle vaccine is safe and elicits functional, non-neutralizing anti-nucleoprotein antibodies and T cell activation in …
A Kleymann, E Karaaslan, FEM Scholte, TE Sorvillo… - Antiviral Research, 2025 - Elsevier
Advancement of vaccine candidates that demonstrate protective efficacy in screening
studies necessitates detailed safety and immunogenicity investigations in pre-clinical …
studies necessitates detailed safety and immunogenicity investigations in pre-clinical …